蹤獲觴豐

Jitendra Kanodia has a diverse work experience in the biopharmaceutical industry. Jitendra is currently a Board Member at IQ Consortium since March 2022. Prior to this, they held the position of Executive Director Head of Clinical and Systems Pharmacology at Xencor starting from December 2021.

Jitendra also worked at Theravance Biopharma US, Inc. where they held multiple roles, including Senior Director from July 2021 to December 2021, Director from August 2019 to July 2021, Associate Director from August 2017 to July 2019, and Senior Scientist from July 2016 to July 2017. During their tenure at Theravance Biopharma, they were involved in developing development strategies, designing clinical strategies, leading biomarker-subteams, and developing early clinical strategies for various drug products.

Before joining Theravance Biopharma, Jitendra worked as a Fellow at Nassau Street Ventures from July 2020 to July 2021. Jitendra was responsible for raising capital from Princeton alumni and investing in alumni-led startups.

Jitendra's previous experience includes working as a Scientist at Genentech from August 2014 to July 2016. In this role, they led a team and was responsible for the non-clinical strategy, IND submission, and executing the Phase 1 study. Jitendra was also involved in pre-clinical and translational PKPD modeling and PK lead for various programs.

Jitendra started their career as a Senior Scientist at Merrimack Pharmaceuticals from December 2011 to August 2014.

Jitendra Kanodia completed their education in a chronological manner, starting with their Bachelor of Technology (BTech) and Master of Technology (MTech) degrees in Chemical Engineering from the Indian Institute of Technology, Madras. Jitendra studied at this institution from 2002 to 2007. Subsequently, they pursued a Doctor of Philosophy (PhD) degree in Chemical and Biological Engineering at Princeton University, from 2007 to 2011.